当前位置： SCI文献检索 > VACCINE期刊下所有文献 > The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012.

The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012.

Abstract：

BACKGROUND:Few studies report the effectiveness of trivalent inactivated influenza vaccine (TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a prospective surveillance platform, this study reports the first such estimate from a well-defined ethnically diverse population in New Zealand (NZ). METHODS:A case test-negative design was used to estimate propensity adjusted vaccine effectiveness. Patients with a severe acute respiratory infection (SARI), defined as a patient of any age requiring hospitalisation with a history of a fever or a measured temperature ≥38°C and cough and onset within the past 7 days, admitted to public hospitals in South and Central Auckland were eligible for inclusion in the study. Cases were SARI patients who tested positive for influenza, while non-cases (controls) were SARI patients who tested negative. Results were adjusted for the propensity to be vaccinated and the timing of the influenza season. RESULTS:The propensity and season adjusted vaccine effectiveness (VE) was estimated as 39% (95% CI 16;56). The VE point estimate against influenza A (H1N1) was lower than for influenza B or influenza A (H3N2) but confidence intervals were wide and overlapping. Estimated VE was 59% (95% CI 26;77) in patients aged 45-64 years but only 8% (-78;53) in those aged 65 years and above. CONCLUSION:Prospective surveillance for SARI has been successfully established in NZ. This study for the first year, the 2012 influenza season, has shown low to moderate protection by TIV against influenza positive hospitalisation.

journal_name

Vaccine

journal_title

Vaccine

authors

Turner N,Pierse N,Bissielo A,Huang QS,Baker MG,Widdowson MA,Kelly H,SHIVERS investigation team.

doi

10.1016/j.vaccine.2014.04.013

subject

Has Abstract

pub_date

2014-06-17 00:00:00

pages

3687-93

issue

29

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(14)00515-5

journal_volume

32

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Observational study of vaccine effectiveness 20 years after the introduction of universal hepatitis B vaccination in Tunisia.

    abstract：OBJECTIVES:The objectives of this study were to estimate the national prevalence of hepatitis B infection in Tunisia using data from a nationwide survey, to compare results with those obtained in 1996 survey and to evaluate the impact of vaccination twenty years after its introduction. METHODS:A National household-bas...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.08.038

    authors： Ben Hadj M,Bouguerra H,Saffar F,Chelly S,Hechaichi A,Talmoudi K,Bahrini A,Chouki T,Hazgui O,Hannachi N,Letaief H,Bellali H,Bahri O,Ben-Alaya-Bouafif N

    更新日期：2018-09-18 00:00:00

  • Introducing cholera vaccination in Asia, Africa and Haiti: a meeting report.

    abstract：:Orally-administered cholera vaccine (OCV) has been increasingly examined as an additional tool to intervene against endemic and epidemic cholera. In 2013, short- and long-term field experience with OCV under nine distinctive field settings was reported from India, Bangladesh, Vietnam, Guinea, Haiti, and Thailand. Lead...

    journal_title：Vaccine

    pub_type：

    doi：10.1016/j.vaccine.2014.11.031

    authors： Hall RH,Sack DA

    更新日期：2015-01-15 00:00:00

  • Use of administrative records to assess pneumococcal conjugate vaccine impact on pediatric meningitis and pneumonia hospitalizations in Rwanda.

    abstract：BACKGROUND:Ongoing surveillance is critical to assessing pneumococcal conjugate vaccine (PCV) impact over time. However, robust prospective studies are difficult to implement in resource-poor settings. We evaluated retrospective use of routinely collected data to estimate PCV impact in Rwanda. METHODS:We collected dat...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.08.084

    authors： Gatera M,Uwimana J,Manzi E,Ngabo F,Nwaigwe F,Gessner BD,Moïsi JC

    更新日期：2016-10-17 00:00:00

  • Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives.

    abstract：:In HIV vaccine trials, the collection and analysis of participant behavior data associated with risk of acquiring HIV-infection is important for a number of reasons. Although the rationale for behavioral risk assessment in HIV vaccine clinical trials is clear, consistent collection of behavioral data over time and acr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.07.003

    authors： Andrasik MP,Karuna ST,Nebergall M,Koblin BA,Kublin JG,NIAID HIV Vaccine Trials Network.

    更新日期：2013-09-13 00:00:00

  • Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.

    abstract：:We report the rationale, design, methods and details of participation of a community-based, double-blind, randomized clinical trial of an HPV 16 and 18 vaccine conducted in two provinces of Costa Rica to investigate the efficacy and population impact of the vaccine in the prevention of cervical cancer precursors. More...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2008.07.002

    authors： Herrero R,Hildesheim A,Rodríguez AC,Wacholder S,Bratti C,Solomon D,González P,Porras C,Jiménez S,Guillen D,Morales J,Alfaro M,Cyr J,Morrisey K,Estrada Y,Cortés B,Morera LA,Freer E,Schussler J,Schiller J,Lowy D,S

    更新日期：2008-09-02 00:00:00

  • Semantic network analysis of vaccine sentiment in online social media.

    abstract：OBJECTIVE:To examine current vaccine sentiment on social media by constructing and analyzing semantic networks of vaccine information from highly shared websites of Twitter users in the United States; and to assist public health communication of vaccines. BACKGROUND:Vaccine hesitancy continues to contribute to subopti...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.05.052

    authors： Kang GJ,Ewing-Nelson SR,Mackey L,Schlitt JT,Marathe A,Abbas KM,Swarup S

    更新日期：2017-06-22 00:00:00

  • Quantitative assay for the transforming DNA activity in cell culture products for human use.

    abstract：:DNA isolates from a number of established cell lines have been tested for their transforming capacity in the NIH3T3 transformation assay. It has been found that this assay can be used to quantify the amount of transforming DNA at a submicrogram to milligram level. This assay system has been applied to validate the red...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(85)90126-4

    authors： van Meel FC,Steenbakkers PG,Bos E

    更新日期：1985-12-01 00:00:00

  • Immune response to bovine viral diarrhea virus (BVDV) vaccines detecting antibodies to BVDV subtypes 1a, 1b, 2a, and 2c.

    abstract：:Bovine viral diarrhea virus (BVDV) represents a major cattle disease with multiple forms including fetal infections resulting in persistently infected (PI) cattle. The objectives of this study were to investigate the immune response to six vaccines, five modified live viral (MLV) and one killed vaccine containing BVDV...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.03.058

    authors： Fulton RW,Cook BJ,Payton ME,Burge LJ,Step DL

    更新日期：2020-05-19 00:00:00

  • Antibodies against Haemophilus influenzae type b in The Gambia: investigating the extent of protection across age groups.

    abstract：:Following a landmark clinical trial, the vaccine against Haemophilus influenzae type b (Hib) was introduced in The Gambia in 1997. Whilst the immunogenicity of this vaccine is well established subsequent to the doses administered under the EPI schedule, little data exists assessing longevity of protection, using serol...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.06.078

    authors： Idoko OT,Roberts E,Cox M,Jafali J,Njie-Jobe J,Mackenzie G,Ota MO,Kampmann B

    更新日期：2014-08-06 00:00:00

  • Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.

    abstract：:Shigella and enterotoxigenic Escherichia coli continue to be significant causes of diarrheal disease in infants and young children in developing countries as well as prevalent agents of traveler's diarrhea. A vaccine which provides protection against disease caused by both pathogens would serve common at-risk populati...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.07.013

    authors： Barry EM,Wang J,Wu T,Davis T,Levine MM

    更新日期：2006-05-01 00:00:00

  • Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules.

    abstract：:The candidate vaccine virus NIBRG-14 was derived by reverse genetics and comprises the haemagglutinin (HA) and neuraminidase (NA) genes derived from the clade 1 virus A/Viet Nam/1194/2004 on an A/Puerto Rico/8/34 (PR8) backbone. The HA gene was modified to remove the multibasic cleavage site motif associated with high...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.09.006

    authors： Harvey R,Nicolson C,Johnson RE,Guilfoyle KA,Major DL,Robertson JS,Engelhardt OG

    更新日期：2010-11-23 00:00:00

  • A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model.

    abstract：:Lassa fever remains the most imported viral haemorrhagic fever in Europe and is responsible for 5000 deaths per year throughout Western Africa. There is no vaccine and treatment is often ineffective. We have developed a vaccine based on modified Vaccinia Ankara expressing the nucleoprotein from Lassa virus (MVALassaNP...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.07.023

    authors： Kennedy EM,Dowall SD,Salguero FJ,Yeates P,Aram M,Hewson R

    更新日期：2019-08-23 00:00:00

  • Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials.

    abstract：:To provide a safer live challenge strain for use in clinical vaccine trials, a double drug sensitive strain of Leishmania major was derived using advances in gene targeting technology by stably introducing into the chromosome a modified HSV-1 thymidine kinase gene (tk), conferring increased sensitivity to ganciclovir ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.08.032

    authors： Davoudi N,Tate CA,Warburton C,Murray A,Mahboudi F,McMaster WR

    更新日期：2005-01-19 00:00:00

  • Protection capability of recombinant plasmid DNA vaccine containing VP2 gene of very virulent infectious bursal disease virus in chickens adjuvanted with CpG oligodeoxynucleotide.

    abstract：:In the present study the efficacy of recombinant plasmids DNA vaccine encoding VP2 gene of very virulent strain of infectious bursal disease virus (vvIBDV) isolated from Pakistan was investigated with or without coadministration of cytocine-phosphate-guanine oligodeoxynucleotide (CpG ODN) to protect the chickens again...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.03.016

    authors： Mahmood MS,Siddique M,Hussain I,Khan A,Mansoor MK

    更新日期：2006-05-29 00:00:00

  • Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.

    abstract：INTRODUCTION:Pan American Health Organization's (PAHO) ProVac Initiative aims to strengthen countries' technical capacity to make evidence-based immunization policy. With financial support from the Bill and Melinda Gates Foundation, PAHO established the ProVac International Working Group (IWG), a platform created for t...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.10.090

    authors： Jauregui B,Garcia AG,Bess Janusz C,Blau J,Munier A,Atherly D,Mvundura M,Hajjeh R,Lopman B,Clark AD,Baxter L,Hutubessy R,de Quadros C,Andrus JK

    更新日期：2015-05-07 00:00:00

  • Indicators to assess National Immunization Technical Advisory Groups (NITAGs).

    abstract：:A National Immunization Technical Advisory Group (NITAG) is an expert advisory committee that provides evidence-based recommendations to the Ministry of Health (MoH) to guide immunization programs and policies. The World Health Organization (WHO), the Initiative for Supporting National Independent Immunization and Vac...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.01.047

    authors： Blau J,Sadr-Azodi N,Clementz M,Abeysinghe N,Cakmak N,Duclos P,Janusz C,Jauregui B,Mihigo R,Mosina L,Takashima Y,Senouci K

    更新日期：2013-05-28 00:00:00

  • Influenza vaccination rates in Ontario children: implications for universal childhood vaccination policy.

    abstract：:The aims of this study were to estimate influenza vaccination coverage for children during the 2006-2007 influenza season in Ontario, Canada, where universal vaccination is available, and to compare the rate among children aged 6-23 months with corresponding rates from other Canadian provinces that specifically target...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.02.017

    authors： Moran K,Maaten S,Guttmann A,Northrup D,Kwong JC

    更新日期：2009-04-14 00:00:00

  • An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India.

    abstract：:Purified Vero cell culture rabies vaccine "Abhayrab" manufactured by Human Biologicals Institute, Ooty, India was subjected for immunogenicity studies. Pre-exposure study was undertaken on 60 healthy volunteers (Group I) with vaccination on days 0, 7 and 21. A group of 75 patients of category II (Group II), 67 of cate...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.08.001

    authors： Sampath G,Reddy SV,Rao ML,Rao YU,Palaniappan C

    更新日期：2005-01-04 00:00:00

  • Classification of measles cases from 2014 to 2018: Implications for progress towards measles elimination in China.

    abstract：:Measles incidence has decreased dramatically in China due to the implement of measles-containing vaccine (MCV). However, a measles epidemic caused resurgence recently, even among vaccinated individuals. To evaluate the effectiveness of current immunization programs and discuss initiatives for the next step in measles ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.03.049

    authors： Cui A,Zhang Y,Zhu Z,Wang H,Mao N,Song J,Xu W

    更新日期：2020-05-08 00:00:00

  • Interventions to reduce the burden of vaccine-preventable diseases among migrants and refugees worldwide: A scoping review of published literature, 2006-2018.

    abstract：BACKGROUND:Disparities in vaccine-preventable disease (VPD) burden and immunisation coverage between migrants and refugees and their host populations have been described in numerous countries worldwide. Effective strategies are required to reduce the health disparities and immunisation inequities experienced by migrant...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2020.09.054

    authors： Charania NA,Gaze N,Kung JY,Brooks S

    更新日期：2020-10-27 00:00:00

  • Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.

    abstract：:The current human whole-cell vaccine is ineffective against pneumonic plague caused by typical F1 capsule positive (F1+) strains of Yersinia pestis. The authors found this vaccine to also be ineffective against F1-negative (F1-) Y. pestis strains, which have been isolated from a human case and from rodents. For these ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)80110-2

    authors： Heath DG,Anderson GW Jr,Mauro JM,Welkos SL,Andrews GP,Adamovicz J,Friedlander AM

    更新日期：1998-07-01 00:00:00

  • Expression of human antibodies in eukaryotic micro-algae.

    abstract：:Protein based therapeutics have enjoyed great success over the past decade. Unfortunately, with this clinical success comes a heavy price tag, owing to the inherently high costs of capitalization and production using mammalian cell fermentation. To address this problem, we have begun developing a system for the expres...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2004.11.013

    authors： Mayfield SP,Franklin SE

    更新日期：2005-03-07 00:00:00

  • Safety of yellow fever vaccine administration in confirmed egg-allergic patients.

    abstract：:Yellow fever vaccine (YFV) is recommended in endemic areas but represents a risk for egg-allergic patients, as it is cultivated in embryonated eggs. This study aims to describe the outcomes of yellow fever vaccination in patients with confirmed egg allergy (EA). Methods:A prospective study was conducted from January 2...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.08.020

    authors： Gerhardt CMB,Castro APBM,Pastorino AC,Dorna MB,Nunes-Santos CJ,Aquilante BP,Miyaji KT,Lopes MH

    更新日期：2020-09-29 00:00:00

  • Provider time and costs to vaccinate adult patients: Impact of time counseling without vaccination.

    abstract：:Amid provider reports of financial barriers as an impediment to adult immunization, this study explores the time and costs of vaccination in adult provider practices. Both a Vaccination Time-Motion Study and Vaccine Practice Management Survey were conducted (March - October 2017) in a convenience sample of 19 family m...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.12.045

    authors： Shen A,Khavjou O,King G,Bates L,Zhou F,Leidner AJ,Yarnoff B

    更新日期：2019-02-04 00:00:00

  • Defining hard-to-reach populations for vaccination.

    abstract：:Extending the benefits of vaccination to everyone who is eligible requires an understanding of which populations current vaccination efforts have struggled to reach. A clear definition of "hard-to-reach" populations - also known as high-risk or marginalized populations, or reaching the last mile - is essential for est...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2019.06.081

    authors： Ozawa S,Yemeke TT,Evans DR,Pallas SE,Wallace AS,Lee BY

    更新日期：2019-09-03 00:00:00

  • Targeted expression of HTLV-I envelope proteins in muscle by DNA immunization of mice.

    abstract：:We have compared two types of plasmids for DNA immunization against HTLV-I envelope glycoproteins. One type of plasmid contains the coding DNA of the complete envelope gene of HTLV-I under the control of the CMV promoter with (CMVenvLTR) or without (CMVenv) the tax/rex genes. The second type contains the coding DNA of...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(99)00565-4

    authors： Armand MA,Grange MP,Paulin D,Desgranges C

    更新日期：2000-04-28 00:00:00

  • Streptococcus pneumoniae serotypes in Utah adults at the end of the PCV7 era.

    abstract：:While heptavalent pneumococcal conjugate vaccine (PCV) has decreased vaccine type invasive pneumococcal disease (IPD) nationwide, rapid serotype replacement and increasing parapneumonic empyema, has been reported in Utah children. The effect of pediatric vaccination on adults in this population is unknown. We identifi...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.10.009

    authors： Kendall BA,Dascomb KK,Mehta RR,Mason EO,Ampofo K,Pombo DJ,Pavia AT,Byington CL

    更新日期：2011-11-15 00:00:00

  • An E2 sub-unit marker vaccine does not prevent horizontal or vertical transmission of classical swine fever virus.

    abstract：:An experimental infection with classical swine fever (CSF) virus in E2 sub-unit marker vaccine vaccinated gilts was conducted in order to evaluate the effect of vaccination on virus transmission and course of the disease. Therefore, clinical signs as well as horizontal and vertical virus transmission were monitored in...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00320-6

    authors： Dewulf J,Laevens H,Koenen F,Mintiens K,de Kruif A

    更新日期：2001-10-12 00:00:00

  • Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge.

    abstract：:Strains of Newcastle disease virus (NDV) can be separated into genotypes based on genome differences even though they are antigenically considered to be of a single serotype. It is widely recognized that an efficacious Newcastle disease (ND) vaccine made with any NDV does induce protection against morbidity and mortal...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.07.017

    authors： Miller PJ,King DJ,Afonso CL,Suarez DL

    更新日期：2007-10-10 00:00:00

  • The immunogenicity-enhancing effect of emulsion vaccine adjuvants is independent of the dispersion type and antigen release rate--a revisit of the role of the hydrophile-lipophile balance (HLB) value.

    abstract：:Effective antigen delivery is one of the most important issues in vaccine development. It has been suggested that adjuvant action results from a depot effect by prolonging the duration of the interaction between antigen and cells, and thus is related to the antigen-releasing properties of emulsion adjuvants. The objec...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.09.007

    authors： Yang YW,Wei AC,Shen SS

    更新日期：2005-04-08 00:00:00